Cyxone strengthens team ahead of continued development of the drug projects and the company
Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company is expanding its team with Christin Arrhenius Bokedal as Head of Development for the next step in the development of Cyxone's clinical drug portfolio. Christin will primarily lead and coordinate the preclinical and clinical development programs in the company.
Christin Arrhenius Bokedal holds a master degree in pharmacy from Uppsala University. During her career, Christin has accumulated extensive and diverse experience in drug development from her positions within Regulatory Affairs, Quality Assurance, Medical Affairs and project management.
Malin Berthold, Cyxone’s COO, commented: “We see that Christin will bring great extensive experience to the company thanks to her broad expertise in project management, preclinical and clinical studies and her solid experience in medical information, regulatory affairs and quality assurance. Her broad knowledge in drug development together with her ability to get things done with remained high quality and focus will be a great asset for Cyxone, which is currently in an incredibly exciting development and growth phase.”
Christin most recently worked for Teva Sweden, a leading international company in CNS, respiratory diseases and oncology. She begins her role at Cyxone not later than 2 October 2020.
Contact
Cyxone AB (publ)
Tara Heitner, CEO
Tel: +46 (0) 707 81 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden
About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se. www.cyxone.com
Tags: